US FDA approves Omeros' drug to treat dangerous transplant complication

The U.S. Food and Drug Administration has approved Omeros' drug for a dangerous transplant complication in adults and ...
Fierce Pharma

Omeros scores its first-ever FDA nod for stem cell transplant drug Yartemlea

Four years after Omeros came up short in its bid to gain an FDA approval for stem cell transplant drug narsoplimab, the ...

FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® ...

Omeros surges on FDA nod for transplant therapy (update)

Omeros (OMER) stock in focus as the FDA approves its lead asset as Yartemlea for a complication related to stem cell ...

FDA Approves Omeros' First-In-Class Drug For Rare Transplant Complication

The U.S. Food and Drug Administration (FDA) on Wednesday approved Omeros Corporation (NASDAQ: OMER) Yartemlea ...

FDA Approves Omeros' YARTEMLEA(R) -- First and Only Therapy Indicated for TA-TMA

Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...

Omeros: Stock Pops On Yartemlea Approval, Longer-Term Upside Likely

Omeros (OMER) receives FDA approval for Yartemlea (narsoplimab) in TA-TMA, driving shares up nearly 80% to a $1bn+ valuation.
The Pharma Letter

Omeros rockets as FDA approves Yartemlea

Seattle, USA-based biotech Omeros Corp saw its shares leap 75.5% to $15.36 by close of trading Wednesday, as it revealed that ...

Omeros Gets FDA Approval of Yartemlea

Omeros on Wednesday said the approval covers Yartemlea for patients ages 2 and older with hematopoietic stem-cell transplant-associated thrombotic microangiopathy, a complication driven by the ...

Why Omeros (OMER) Is Up 74.0% After First-In-Class TA-TMA Drug Wins FDA Approval

Earlier this month, Omeros Corporation announced that the FDA approved YARTEMLEA (narsoplimab-wuug), the first and only therapy for hematopoietic stem cell transplant-associated thrombotic ...
BioWorld

FDA approves Omeros’ Yartemlea for stem cell patients

The U.S. FDA’s green lighting of Omeros Corp.’s Yartemlea (narsoplimab) makes it the first approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a ...